Search Articles

View query in Help articles search

Search Results (1 to 2 of 2 Results)

Download search results: CSV END BibTex RIS


Tracking Public Interest in Rare Diseases and Eosinophilic Disorders in Germany: Web Search Analysis

Tracking Public Interest in Rare Diseases and Eosinophilic Disorders in Germany: Web Search Analysis

Diagnosis is typically based on the exclusion of other causes of eosinophilia (eg, allergic diseases or parasitic infections) and histopathological and immunohistochemical studies, permitting classification in the following subtypes: myeloproliferative (M-HES), lymphocytic (L-HES), idiopathic (I-HES), and chronic eosinophilic leukemia not otherwise specified (CEL-NOS). [1,10].

Michael Hindelang, Sebastian Sitaru, Alexander Zink

JMIR Infodemiology 2025;5:e69040

Cyclosporine in the Treatment of Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome: Retrospective Cohort Study

Cyclosporine in the Treatment of Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome: Retrospective Cohort Study

Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome causes severe cutaneous and systemic complications with a mortality rate of ≈10% [1,2]. The current standard of care for DRESS syndrome involves the removal of the culprit drug, supportive therapy, and systemic corticosteroids. Corticosteroid therapy must be tapered for weeks to months to prevent DRESS syndrome relapse [1].

Sophia Zita, Lindsey Broussard, Jeremy Hugh, Sabrina Newman

JMIR Dermatol 2023;6:e41391